195 related articles for article (PubMed ID: 23716351)
1. Distinct molecular profiles in Lynch syndrome-associated and sporadic ovarian carcinomas.
Niskakoski A; Kaur S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
Int J Cancer; 2013 Dec; 133(11):2596-608. PubMed ID: 23716351
[TBL] [Abstract][Full Text] [Related]
2. Breast carcinoma and Lynch syndrome: molecular analysis of tumors arising in mutation carriers, non-carriers, and sporadic cases.
Lotsari JE; Gylling A; Abdel-Rahman WM; Nieminen TT; Aittomäki K; Friman M; Pitkänen R; Aarnio M; Järvinen HJ; Mecklin JP; Kuopio T; Peltomäki P
Breast Cancer Res; 2012 Jun; 14(3):R90. PubMed ID: 22691310
[TBL] [Abstract][Full Text] [Related]
3. Redundant DNA methylation in colorectal cancers of Lynch-syndrome patients.
Alemayehu A; Sebova K; Fridrichova I
Genes Chromosomes Cancer; 2008 Oct; 47(10):906-14. PubMed ID: 18618713
[TBL] [Abstract][Full Text] [Related]
4. BRAF/KRAS gene sequencing of sebaceous neoplasms after mismatch repair protein analysis.
Cornejo KM; Hutchinson L; Deng A; Tomaszewicz K; Welch M; Lyle S; Dresser K; Cosar EF
Hum Pathol; 2014 Jun; 45(6):1213-20. PubMed ID: 24767862
[TBL] [Abstract][Full Text] [Related]
5. Genetic mechanisms in interval colon cancers.
Richter JM; Pino MS; Austin TR; Campbell E; Szymonifka J; Russo AL; Hong TS; Borger D; Iafrate AJ; Chung DC
Dig Dis Sci; 2014 Sep; 59(9):2255-63. PubMed ID: 24705641
[TBL] [Abstract][Full Text] [Related]
6. Targeted gene sequencing of Lynch syndrome-related and sporadic endometrial carcinomas.
Libera L; Craparotta I; Sahnane N; Chiaravalli AM; Mannarino L; Cerutti R; Riva C; Marchini S; Furlan D
Hum Pathol; 2018 Nov; 81():235-244. PubMed ID: 30420047
[TBL] [Abstract][Full Text] [Related]
7. Lynch syndrome--related endometrial carcinomas show a high frequency of nonendometrioid types and of high FIGO grade endometrioid types.
Carcangiu ML; Radice P; Casalini P; Bertario L; Merola M; Sala P
Int J Surg Pathol; 2010 Feb; 18(1):21-6. PubMed ID: 19443869
[TBL] [Abstract][Full Text] [Related]
8. The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy.
Chui MH; Ryan P; Radigan J; Ferguson SE; Pollett A; Aronson M; Semotiuk K; Holter S; Sy K; Kwon JS; Soma A; Singh N; Gallinger S; Shaw P; Arseneau J; Foulkes WD; Gilks CB; Clarke BA
Am J Surg Pathol; 2014 Sep; 38(9):1173-81. PubMed ID: 25025451
[TBL] [Abstract][Full Text] [Related]
9. Lynch syndrome-associated colorectal carcinoma: frequent involvement of the left colon and rectum and late-onset presentation supports a universal screening approach.
Hartman DJ; Brand RE; Hu H; Bahary N; Dudley B; Chiosea SI; Nikiforova MN; Pai RK
Hum Pathol; 2013 Nov; 44(11):2518-28. PubMed ID: 24034859
[TBL] [Abstract][Full Text] [Related]
10. Cancer risk and overall survival in mismatch repair proficient hereditary non-polyposis colorectal cancer, Lynch syndrome and sporadic colorectal cancer.
Garre P; Martín L; Bando I; Tosar A; Llovet P; Sanz J; Romero A; de la Hoya M; Díaz-Rubio E; Caldés T
Fam Cancer; 2014 Mar; 13(1):109-19. PubMed ID: 24061861
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.
Niskakoski A; Kaur S; Staff S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
Epigenetics; 2014 Dec; 9(12):1577-87. PubMed ID: 25625843
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas.
Shikama A; Minaguchi T; Matsumoto K; Akiyama-Abe A; Nakamura Y; Michikami H; Nakao S; Sakurai M; Ochi H; Onuki M; Satoh T; Oki A; Yoshikawa H
Gynecol Oncol; 2016 Feb; 140(2):226-33. PubMed ID: 26644264
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.
Kloor M; Huth C; Voigt AY; Benner A; Schirmacher P; von Knebel Doeberitz M; Bläker H
Lancet Oncol; 2012 Jun; 13(6):598-606. PubMed ID: 22552011
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome.
Huang M; Djordjevic B; Yates MS; Urbauer D; Sun C; Burzawa J; Daniels M; Westin SN; Broaddus R; Lu K
Cancer; 2013 Aug; 119(16):3027-33. PubMed ID: 23760948
[TBL] [Abstract][Full Text] [Related]
15. Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries.
Ryan P; Mulligan AM; Aronson M; Ferguson SE; Bapat B; Semotiuk K; Holter S; Kwon J; Kalloger SE; Gilks CB; Gallinger S; Pollett A; Clarke BA
Cancer; 2012 Feb; 118(3):681-8. PubMed ID: 21721000
[TBL] [Abstract][Full Text] [Related]
16. Alternate molecular genetic pathways in ovarian carcinomas of common histological types.
Willner J; Wurz K; Allison KH; Galic V; Garcia RL; Goff BA; Swisher EM
Hum Pathol; 2007 Apr; 38(4):607-13. PubMed ID: 17258789
[TBL] [Abstract][Full Text] [Related]
17. Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors.
Ketabi Z; Bartuma K; Bernstein I; Malander S; Grönberg H; Björck E; Holck S; Nilbert M
Gynecol Oncol; 2011 Jun; 121(3):462-5. PubMed ID: 21388660
[TBL] [Abstract][Full Text] [Related]
18. The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms.
Borie C; Colas C; Dartigues P; Lazure T; Rince P; Buhard O; Folliot P; Chalastanis A; Muleris M; Hamelin R; Mercier D; Oliveira C; Seruca R; Chadburn A; Leblond V; Barete S; Gaïdano G; Martin A; Gaulard P; Fléjou JF; Raphael M; Duval A
Int J Cancer; 2009 Nov; 125(10):2360-6. PubMed ID: 19551857
[TBL] [Abstract][Full Text] [Related]
19. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.
Skeldon SC; Semotiuk K; Aronson M; Holter S; Gallinger S; Pollett A; Kuk C; van Rhijn B; Bostrom P; Cohen Z; Fleshner NE; Jewett MA; Hanna S; Shariat SF; Van Der Kwast TH; Evans A; Catto J; Bapat B; Zlotta AR
Eur Urol; 2013 Feb; 63(2):379-85. PubMed ID: 22883484
[TBL] [Abstract][Full Text] [Related]
20. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer.
Bosse T; ter Haar NT; Seeber LM; v Diest PJ; Hes FJ; Vasen HF; Nout RA; Creutzberg CL; Morreau H; Smit VT
Mod Pathol; 2013 Nov; 26(11):1525-35. PubMed ID: 23702729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
